coronary artery disease
The Finnish diagnostics company is working to expand US and European sales of its ceramide lipid-based cardiovascular risk assessment assay, CERT.
The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of the test as an LDT.
The company has been focused on commercializing its technology for heart attack assessment, but the new data shows how it could be used for CAD risk, as well.
Polygenic SNP Score Correlates With Early-Onset Coronary Artery Disease Risk
Investigators came up with a 182-variant risk score for early-onset coronary artery disease, which they tested on SNP data from UK Biobank participants with or without the condition.
Since it launched CADscor, which could compete against molecular tests, in the second quarter, Acarix has announced clients in Germany, Denmark, and Sweden.